Furin Drives Colorectal Cancer Progression and Chemoresistance Through the TGF-β/ERK Signaling Pathway
Cells · 2025
DOI: 10.3390/cells15010043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Pratheesh Kumar Poyil und 9 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Therapeutics, Innovation & Research, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia. Hauptthemen laut MEDLINE: Furin, Colorectal Neoplasms, Transforming Growth Factor beta, Drug Resistance, Neoplasm. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Colorectal cancer (CRC) remains one of the most lethal malignancies worldwide, with 5-fluorouracil (5-Fu) as a mainstay of treatment. However, intrinsic and acquired resistance to 5-Fu significantly limits therapeutic success. Furin, a proprotein convertase, is known to activate multiple substrates critical for tumor progression, yet its precise role in CRC remains unclear. In this study, we examined furin expression in a large cohort of CRC patient samples and performed functional analyses in CRC cell lines and xenograft models. Furin overexpression was seen in 46.9% (530/1131) of CRC cases and was significantly correlated with TGF-β and ERK1/2 activation. In vitro, induced furin overexpression enhanced proliferation and clonogenicity, accompanied by upregulation of TGF-β and ERK1/2 phosphorylation, whereas furin silencing attenuated tumor cell growth and TGF-β/ERK signaling. Manipulation of TGF-β revealed a reciprocal regulatory loop, whereby TGF-β upregulated furin expression, establishing a feed-forward circuit that augmented ERK signaling and tumor growth. Notably, 5-Fu-resistant CRC cell lines displayed elevated furin, TGF-β, and phospho-ERK1/2, while furin knockdown restored drug sensitivity. In vivo, furin overexpression enhanced tumor growth in xenografts, whereas its depletion markedly reduced tumor burden and TGF-β/ERK signaling activity. Collectively, these findings demonstrate that furin promotes CRC progression and chemoresistance through a positive feedback loop with TGF-β that sustains ERK activation. Targeting furin, alone or in combination with TGF-β/ERK inhibitors, may offer a promising therapeutic strategy for CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Therapeutics, Innovation & Research, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
- Translational Oncology Research, Innovation & Research, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
- Human Cancer Genomic Research, Innovation & Research, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
- Department of Pathology, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
ORCID-Profile: Pratheesh Kumar Poyil, Saud Azam, Khawla S Al-Kuraya
Zitieren
APA
Poyil, P. K., Siraj, A. K., Parvathareddy, S. K., Begum, R., Naidu, P. A., Thangavel, S., Alobaisi, K., Azam, S., Al-Dayel, F., & Al-Kuraya, K. S. (2025). Furin Drives Colorectal Cancer Progression and Chemoresistance Through the TGF-β/ERK Signaling Pathway. Cells. https://doi.org/10.3390/cells15010043
Vancouver
Poyil PK, Siraj AK, Parvathareddy SK, Begum R, Naidu PA, Thangavel S, et al. Furin Drives Colorectal Cancer Progression and Chemoresistance Through the TGF-β/ERK Signaling Pathway. Cells. 2025. doi:10.3390/cells15010043
BibTeX
@article{Poyil2025,
author = {Poyil, Pratheesh Kumar and Siraj, Abdul K and Parvathareddy, Sandeep Kumar and Begum, Rafia and Naidu, Padmanaban Annaiyappa and Thangavel, Saravanan and Alobaisi, Khadija and Azam, Saud and Al-Dayel, Fouad and Al-Kuraya, Khawla S},
title = {Furin Drives Colorectal Cancer Progression and Chemoresistance Through the TGF-β/ERK Signaling Pathway},
journal = {Cells},
year = {2025},
doi = {10.3390/cells15010043}
}
EUVIMED